menu
    • menu
    [{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"tLNP-medicated In-vivo CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Capstan Therapeutics \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Therapeutics \/ Novartis Venture Fund"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"tLNP-medicated In-vivo CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Capstan Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"CPTX2309","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Capstan Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Therapeutics \/ RA Capital Management"}]

    Find Clinical Drug Pipeline Developments & Deals by Capstan Therapeutics

    Menu

    Capstan Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Capstan Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Capstan Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CPTX2309

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $175.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Capstan Therapeutics Announces $175M Oversubscribed Series B Financing

                            Details : Proceeds will advance CPTX2309, Capstan’s CAR-T candidate, to early clinical proof-of-concept in autoimmune disorders and develop its tLNP pipeline.

                            Brand Name : CPTX2309

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 20, 2024

                            Lead Product(s) : CPTX2309

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $175.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Capstan Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Capstan Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : tLNP-medicated In-vivo CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Novartis Venture Fund

                            Deal Size : $63.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Starry Syndicate Powers $165M Bet on In Vivo CAR-T Therapies

                            Details : Capstan’s modular platform leverages the biological and technological expertise of its founding scientists and includes proprietary targeted lipid nanoparticles (tLNP) technology.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 14, 2022

                            Lead Product(s) : tLNP-medicated In-vivo CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Novartis Venture Fund

                            Deal Size : $63.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Capstan Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Capstan Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : tLNP-medicated In-vivo CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Pfizer Ventures

                            Deal Size : $102.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Eng...

                            Details : The company plans to use the funds to further its mission of advancing the clinical promise of cell-based therapies by enabling precise in vivo engineering of cells with payloads necessary to benefit patients across multiple disease categories.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 14, 2022

                            Lead Product(s) : tLNP-medicated In-vivo CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Pfizer Ventures

                            Deal Size : $102.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth